Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · INDRAYANI BIOTECH LTD. · 7 November 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
INDRAYANI BIOTECH LTD.
BSE: 526445
BSE: 526445
Fast Moving Consumer Goods › Fast Moving Consumer Goods › Agricultural Food & other Products › Other Agricultural Products
INDRAYANI BIOTECH LTD.
StateQ1 FY27 filed
Last close · 6 Nov 2026₹7.93
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA19.8 · 0.35 · 18.0
INDRAYANI BIOTECH LTD. is a Agricultural Food & other Products company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 62 | 163 | 166 | 130 | 138 |
| EBITDA (ex other income) | 7 | 17 | 23 | 6 | 10 |
| margin % | 11.0 | 10.3 | 14.1 | 4.8 | 7.0 |
| Owners' profit | 4 | 9 | 0 | (6) | 0 |
| EPS, as reported (₹) | 1.30 | 2.55 | 1.40 | (1.35) | 0.48 |
| ROE % · ROCE % | 18.1 · 19.8 | 24.7 · 21.3 | 13.7 · 14.1 | (6.1) · 3.6 | 1.9 · 6.2 |
| Debt / equity (x) | 0.73 | 1.30 | 1.41 | 1.37 | 1.26 |
| Cash from operations | 4 | 16 | (30) | (7) | 32 |
| Capex | (1) | (18) | (16) | (1) | (8) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · INDRAYANI BIOTECH LTD. · 7 November 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31 | 17 | 51 | 29 | 36 | 35 | 38 | 38 |
| Profit before tax | 1 | 0 | (8) | 0 | 1 | 0 | (1) | 1 |
| Net profit | 1 | 0 | (9) | 0 | 1 | 0 | 1 | 1 |
| EPS (₹) | 0.13 | 0.05 | (1.42) | 0.03 | 0.09 | 0.01 | 0.24 | 0.06 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| LT FOODS LIMITED | 14,628 | 22.3 | 2.98 | 13.3 | 7.4 | 8.4 | 18.7 | 10.5 |
| KRBL LIMITED | 9,339 | 11.1 | 1.50 | 10.4 | 8.3 | 10.9 | 8.8 | 19.2 |
| GUJARAT AMBUJA EXPORTS LT | 6,881 | 13.5 | 1.92 | 15.7 | 8.6 | 11.0 | 4.0 | 13.6 |
| KAVERI SEED CO. LTD. | 3,528 | 13.9 | 1.74 | 10.3 | 13.4 | 13.3 | 6.1 | 0.3 |
| TRUALT BIOENERGY LIMITED | 3,036 | 13.7 | 1.80 | 15.8 | 5.6 | 4.5 | — | 12.5 |
| AMIR CHAND JAG KUM (E) L | 2,470 | 16.9 | 2.49 | 14.3 | 7.8 | 9.7 | — | 10.7 |
| GRM OVERSEAS LIMITED | 1,927 | 14.7 | 3.18 | 25.1 | 12.3 | 16.5 | 17.2 | 8.3 |
| SANSTAR LIMITED | 1,878 | 47.6 | 2.07 | — | 1.7 | 2.2 | — | 3.8 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.8 | 12.2 | 41 of 53 | 23% |
| P/B | 0.3 | 1.6 | 6 of 52 | 90% |
| ROCE | 0.2 | 2.8 | 44 of 61 | 28% |
| ROE | 1.9 | 2.4 | 27 of 51 | 48% |
| Debt / Equity | 1.3 | 0.2 | 44 of 52 | 16% |
| EBITDA margin | 3.9 | 8.6 | 41 of 57 | 29% |
| Revenue growth | 29.6 | 15.0 | 16 of 52 | 71% |
| Profit growth | 245.1 | 17.0 | 6 of 51 | 90% |
| Market cap | 36 | 66 | 40 of 69 | 43% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · INDRAYANI BIOTECH LTD. · 7 November 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 7 Nov 2026 · Annual report cites funding constraints and six subsidiary transaction approvals | results | high | — | — |
| 6 Nov 2026 · FY26 annual report flags funding strain and six subsidiary approvals | board shareholder meetings | low | — | — |
| 6 Nov 2026 · Indrayani Biotech 34th AGM set for November 30, 2026 | board shareholder meetings | low | — | — |
| 6 Nov 2026 · 34th AGM set for November 30, 2026; book closure and remote voting announced | board shareholder meetings | low | — | — |
| 6 Nov 2026 · Book closure and remote e-voting for 34th AGM on November 30 | board shareholder meetings | low | — | — |
| 6 Nov 2026 · Board sets 34th AGM and recommends six related-party deals for shareholder vote | board shareholder meetings | low | — | — |
| 6 Nov 2026 · BSE approves listing of 83.64 lakh rights shares | capital market events | medium | — | — |
| 3 Nov 2026 · Rights Issue allotment finalised for 8,364,036 shares | corporate actions | high | — | — |
| 3 Nov 2026 · Rights Issue Committee approves allotment of 83,64,036 shares | corporate actions | medium | — | — |
| 3 Nov 2026 · Board to approve notice of 34th Annual General Meeting | compliance | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in